CIVIC: University of Georgia Center for Influenza Vaccine Research in High Risk Populations

该合同计划的目标是支持提高季节性流感疫苗的免疫原性和耐用性，并支持开发创新的流感疫苗方法，提供强大、持久、广泛保护的粘膜和系统抗流感免疫(“通用流感疫苗”)。这将通过NIAID支持的协同流感疫苗创新中心(CIVICS)完成。每个CIRITE将通过临床前动物研究、早期临床试验和健康志愿者人体挑战研究，支持基于对流感候选疫苗的详细免疫学评估的迭代疫苗设计，以将最有希望的候选疫苗推进到I/II阶段临床试验。佐治亚大学高危人群流感疫苗研究中心(CIVR-HRP)建立在主要研究人员多年合作的基础上，提出了一项全面的研究计划，以确定对所有人群具有广泛保护性的流感疫苗，重点是我们最脆弱的人群。该项目结合了知名和初级研究人员的技能，并结合了我们在疫苗开发、病毒学、免疫学、动物模型、验证分析和试剂开发、系统生物学、生物信息学和结构生物学方面的历史长处，及其广泛和世界级的设施和资源，包括圣裘德儿童研究医院(SJCRH)的GMP设施，其新颖和创新的研究设计，如全面评估免疫和组学对疫苗接种的反应，新的平台和佐剂，以及探索高危人群保护性免疫的免疫相关性。

The objective of this contract program is to support improvements in the immunogenicity and durability of seasonal influenza vaccines, and the development of innovative influenza vaccine approaches that provide robust, durable, broadly protective mucosal and systemic anti-influenza immunity (“universal influenza vaccines”). This will be done through NIAID-supported Collaborative Influenza Vaccine Innovation Centers (CIVICs). Each CIVIC will support iterative vaccine design based on detailed immunologic assessment of influenza vaccine candidates through pre-clinical animal studies, early phase clinical trials and healthy volunteer human challenge studies to advance the most promising vaccine candidates into Phase I/II clinical trials. University of Georgia’s Center for Influenza Vaccine Research in High Risk Populations (CIVR-HRP) builds upon many years of collaborative work by the primary investigators, and proposes a comprehensive research program centering on identifying broadly protective influenza vaccines for all populations with a focus on our most vulnerable populations. The program couples the skills of established and junior investigators, and combines our historical program strengths in vaccine development, virology, immunology, animal models, validated assay and reagent development, systems biology, bioinformatics and structural biology, and their extensive and world-class facilities and resources including St Jude Children’s Research Hospital (SJCRH) GMP facility with novel and innovative study designs such as comprehensive assessment of immune and omics responses to vaccination, novel platforms and adjuvants, and exploration of immune correlates of protective immunity in high-risk populations.